Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital

Neurogene Inc. (NASDAQ:NGNE) – Analysts at Lifesci Capital dropped their Q1 2026 EPS estimates for Neurogene in a report issued on Tuesday, March 24th. Lifesci Capital analyst P. Dolezal now forecasts that the company will post earnings per share of ($1.26) for the quarter, down from their prior estimate of ($1.19). Lifesci Capital currently has a “Outperform” rating and a $50.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Lifesci Capital also issued estimates for Neurogene’s Q2 2026 earnings at ($1.28) EPS, Q3 2026 earnings at ($1.04) EPS, Q4 2026 earnings at ($1.06) EPS and FY2026 earnings at ($4.59) EPS.

Other research analysts have also issued reports about the company. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Neurogene in a research report on Tuesday, January 13th. Canaccord Genuity Group began coverage on shares of Neurogene in a report on Friday, February 27th. They issued a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $44.00.

Neurogene Trading Down 5.0%

Shares of NASDAQ NGNE opened at $20.35 on Thursday. Neurogene has a 12-month low of $6.88 and a 12-month high of $37.27. The stock’s fifty day simple moving average is $19.52 and its two-hundred day simple moving average is $21.66. The stock has a market capitalization of $316.85 million, a PE ratio of -4.80 and a beta of 1.53.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($1.12) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.08.

Insider Buying and Selling

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,045 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $84,176.45. Following the completion of the transaction, the chief financial officer owned 105,798 shares of the company’s stock, valued at approximately $2,201,656.38. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the sale, the insider owned 30,497 shares of the company’s stock, valued at $634,642.57. The trade was a 18.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 11.64% of the company’s stock.

Institutional Trading of Neurogene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NGNE. BNP Paribas Financial Markets grew its stake in Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Neurogene by 43.6% in the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after purchasing an additional 1,232 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Neurogene during the fourth quarter worth about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Neurogene in the fourth quarter valued at approximately $165,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Key Stories Impacting Neurogene

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $70 price objective for NGNE, providing bullish analyst support even as it modeled FY2027 EPS of ($4.93). This endorsement and high target can help underpin longer-term upside. HC Wainwright Buy/$70 Target
• Positive Sentiment: An MSN/aggregated report flagged a substantial analyst-driven price-target increase (reported as a 37.29% rise to 82.62), signaling at least one firm is materially more optimistic on Neurogene’s longer-term value — a clear positive for investor sentiment and potential catalyst for upside. Neurogene (NGNE) price target increased by 37.29% to 82.62
• Neutral Sentiment: A Globe and Mail roundup included Neurogene in a broader analysts-insights piece; such coverage can raise visibility but didn’t add new company-specific data likely to move the stock by itself. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Lifesci Capital cut Q1–Q4 2026 and FY2026 EPS estimates for NGNE across multiple notes, lowering FY2026 EPS to ($4.59) (from $4.33) while still keeping an “Outperform” rating and a $50 target. Those downward revisions to near-term profitability are a bearish driver and likely the primary reason for today’s weakness. Lifesci Capital EPS revisions / Outperform $50

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.